Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Company Deals

ELI Radiopharma and United Imaging Research Institute Forge Strategic Alliance to Advance Radiopharmaceutical Innovation

Fineline Cube Aug 4, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

CARsgen Therapeutics’ CT0596 Receives NMPA Clinical Approval for Relapsed/Refractory Multiple Myeloma

Fineline Cube Aug 5, 2026
Company Drug

InnoCare Pharma’s Orelabrutinib-Mesutoclax Combination Receives Breakthrough Therapy Designation for Marginal Zone Lymphoma

Fineline Cube Aug 5, 2026
Company Drug

Livzon Pharma’s LZM012 Meets Phase III Endpoint for Psoriasis Treatment

Fineline Cube Jul 22, 2025

China-Based Livzon Pharmaceutical Group, a holding subsidiary of Joincare Pharmaceutical (SHA: 600380) announced that the...

Company Drug

Simcere Zaiming Receives FDA Clearance for Phase I Trial of FGFR2b-Targeting ADC SIM0686

Fineline Cube Jul 22, 2025

China-based Simcere Pharma’s (HKG: 2096) oncology arm, Simcere Zaiming Pharmaceutical, has secured U.S. FDA clearance...

Company

Abbott Reports Q2 2025 Sales of USD 11.14 Billion, Led by Medical Devices Growth

Fineline Cube Jul 22, 2025

Abbott (NYSE: ABT) reported global sales of USD 11.14 billion for the second quarter of...

Company Drug

DualityBio’s Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation

Fineline Cube Jul 22, 2025

Duality Biologics (HKG: 9606) announced that the US Food and Drug Administration (FDA) has granted...

Company Deals

Shanghai Pharma and Cutia Therapeutic Collaborate on Codon Biopharma’s Innovative Drug Distribution

Fineline Cube Jul 22, 2025

China’s Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced the signing of...

Company Drug

Bio-Thera’s BAT4406F Gets NMPA Nod for MCD and FSGS Clinical Trials

Fineline Cube Jul 22, 2025

Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that its investigational drug, BAT4406F injection, has received approval...

Company Drug

Huadong Medicine Receives NMPA Approval for HDM2012 Clinical Trials in Advanced Solid Tumors

Fineline Cube Jul 21, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...

Company Deals Medical Device

Optoseeker Biotech and BioMap Collaborate to Accelerate Antibody Therapeutics Development

Fineline Cube Jul 21, 2025

Optoseeker Biotech, a leader in advanced life science instrumentation, and BioMap, a pioneer in life...

Company Medical Device

Wondfo Biotech’s MSI Detection Kit Granted NMPA Marketing Clearance

Fineline Cube Jul 21, 2025

Guangzhou-based Wondfo Biotech (SHE: 300482) announced that the National Medical Products Administration (NMPA) has granted...

Company Medical Device

Zhongke Yian Receives NMPA Approval for Innovative Sirolimus-Eluting Coronary Stent

Fineline Cube Jul 21, 2025

ZhongKe Yian Medical Technology (Beijing) Co., Ltd. has secured approval from China’s National Medical Products...

Company Drug

NMPA Approves World’s First Plant-Based Human Albumin for Liver Cirrhosis Treatment

Fineline Cube Jul 21, 2025

China’s National Medical Products Administration (NMPA) has approved the world’s first plant-based human albumin, a...

Company Medical Device

KANTE Biotech’s Yilijia Wins NMPA Category III License for Pancreatic Cancer Early Detection

Fineline Cube Jul 21, 2025

KANTE (Shenzhen) Biotechnology Co., Ltd (“Kante-bio”) announced that it has received a Category III medical...

Company

WuXi Biologics Passes FDA Pre-Approval Inspection with Zero Critical Findings

Fineline Cube Jul 21, 2025

WuXi Biologics (HKG: 2269) announced on July 21, 2025, that five of its manufacturing facilities...

Company Drug

Jumpcan Pharmaceutical’s Jike Shu Approved by NMPA for Influenza A and B Treatment

Fineline Cube Jul 21, 2025

Shanghai-based Jumpcan Pharmaceutical (SHA: 600566) announced that its independently developed Class 1 innovative drug, Jike...

Policy / Regulatory

CDE Seeks Feedback on 96th Batch of Chemical Generic Drug Reference Standards

Fineline Cube Jul 21, 2025

China’s Center for Drug Evaluation (CDE) is currently seeking public feedback on the 96th batch...

Company Drug

Novo Nordisk’s Ozempic Approved for Kidney Protection in China, Pioneering Glycemic and Renal Control

Fineline Cube Jul 21, 2025

The National Medical Products Administration has granted approval to Novo Nordisk’s (NYSE: NVO) once-weekly semaglutide...

Company Deals

Shanghai Wankexin Biotech to Acquire Stake in Chengdu Kanghua Biological for RMB 1.851 Billion

Fineline Cube Jul 21, 2025

Shanghai Wankexin Biotechnology Partnership Enterprise (Limited Partnership) (“Wankexin Biotech”), a subsidiary of the Shanghai Biomedicine...

Policy / Regulatory

Hebei Implements Separate Payment for 57 Negotiated Drugs Starting August 1, 2025

Fineline Cube Jul 21, 2025

The Hebei provincial healthcare security administration has issued the “Notice on Improving the Separate Payment...

Company Deals

Bayer and JD Health Collaborate on Dulcolax-Lactulose to Expand China’s Digestive-Health Market

Fineline Cube Jul 21, 2025

Bayer (ETR: BAYN) and JD Health (HKG: 6618) have launched Dulcolax-branded lactulose in a pioneering...

Company Drug

Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension

Fineline Cube Jul 21, 2025

US-based Sarepta Therapeutics, a subsidiary of Sanofi (NASDAQ: SNY), announced the layoff of approximately 500...

Posts pagination

1 … 162 163 164 … 703

Recent updates

  • AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance
  • WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance
  • Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing
  • Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing
  • CARsgen Therapeutics’ CT0596 Receives NMPA Clinical Approval for Relapsed/Refractory Multiple Myeloma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance

Company

WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance

Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.